Table 2. Baseline characteristics of the intention-to-treat population stratified by response to pazopanib.
| Patients with pancreatic NETs with response (n=7) | Patients with pancreatic NETs without response (n=25) | |
|---|---|---|
| Age (years) | 69 (65–76) | 53 (44–60) |
|
| ||
| Sex | ||
| Male | 3 (43%) | 19 (76%) |
| Female | 4 (57%) | 6 (24%) |
|
| ||
| Performance status | ||
| 0 | 2 (29%) | 14 (56%) |
| 1 | 5 (71%) | 11 (44%) |
|
| ||
| Ethnic origin | ||
| White | 7 (100%) | 19 (76%) |
| Black | 0 (0%) | 2 (8%) |
| Hispanic | 0 (0%) | 3 (12%) |
| Native American | 0 (0%) | 1 (4%) |
|
| ||
| Grade | ||
| 1 | 5 (71%) | 18 (72%) |
| 2 | 2 (29%) | 7 (28%) |
|
| ||
| Baseline chromogranin A increased | ||
| Yes | 6 (86%) | 9 (36%) |
| No | 1 (14%) | 14 (56%) |
| Unknown | 0 (0%) | 2 (8%) |
|
| ||
| Time from diagnosis (months) | 31 (18–56) | 30 (13–75) |
|
| ||
| Extent of disease at enrolment | ||
| Unresectable | 0 (0%) | 4 (16%) |
| Metastatic | 7 (100%) | 21 (84%) |
|
| ||
| Progression at enrolment | ||
| Yes | 6 (86%) | 15 (60%) |
| No | 1 (14%) | 10 (40%) |
|
| ||
| Previous therapy | ||
| SSA | 7 (100%) | 25 (100%) |
| Chemotherapy | 5 (71%) | 16 (64%) |
| Everolimus | 2 (29%) | 6 (24%) |
| Liver-directed therapy | 1 (14%) | 2 (8%) |
Data are median (IQR) or n (%) unless otherwise stated. SSA=somatostatin analogue (octreotide).